Dose-response relation confirmed for Holmium-166 (QuiremSpheres™) SIRT

Quirem Medical is pleased to share that yet another Holmium-166 (QuiremSpheres™) related scientific article has been published, after recently having reported on the publication of Smits et al. on the superior predictive value of 166Ho-Scout (QuiremScout™) compared to 99mTc-MAA as a SIRT work-up. This new, corner-stone publication by Bastiaannet et al. has confirmed the premise of a significant dose-response relationship in patients with liver metastases from various origin, treated with QuiremSpheres™ SIRT.

The aim of this study was to analyze the relationship between tumor absorbed dose, treatment response and survival in patients treated with QuiremSpheres™ SIRT. As noted by the authors, the establishment of such a relationship is needed to allow for treatment personalization.

The study included 36 patients with a total of 98 tumors who had been included in either phase 1 and phase 2 Holmium Embolization Particles for Arterial Radiotherapy (HEPAR) studies. Both tumor response and survival were associated significantly with tumor absorbed dose. Moreover, treatment response was found to be associated with a higher overall survival.

“Our findings show that personalized dose optimization, made possible by a holmium-166-scout dose, is likely to have a significant impact on tumor response and overall survival.” says Remco Bastiaannet, MSc, PhD Candidate Medical Physics Radiology and first author of the article.

QuiremSpheres™, the next generation of radio-embolization microspheres, is the only commercially available SIRT product that contains Holmium-166 microspheres. Unlike the widely adopted Yttrium-90 microspheres, Holmium-166 microspheres can be visualized in low concentrations by means of Single Photon Emission Computed Tomography (SPECT) and Magnetic Resonance Imaging (MRI). This allows clinicians to quantitatively assess the distribution of microspheres in the liver, enabling accurate evaluation of treatment directly after the radio-embolization procedure.

Results from this study are published in the Journal of Nuclear Medicine 2019. The full article can be accessed online (external link): DOI: 10.2967/jnumed.119.232751

About Quirem Medical

Quirem Medical is an emerging medical device company with a mission to develop the next generation microspheres for selective internal radiotherapy (SIRT) of liver malignancies.

Quirem Medical BV is a spin-off company of the University Medical Center Utrecht (UMCU) and commercializes, manufactures and distributes a new type of SIRT microspheres based on the isotope holmium, named QuiremSpheres™. QuiremSpheres™ microspheres have received CE mark approval in April 2015 and is currently being used by numerous centers world-wide. In addition, Quirem Medical develops and provides related products, such as Q-Suite™, a CE-marked proprietary software package for converting MRI and SPECT imaging into absorbed dose distributions, and QuiremScout™, a product for SIRT work-up.

Share this post

Share on facebook
Share on twitter
Share on linkedin
Share on pinterest
Share on email

Necessary cookies help make a website more usable by enabling basic functions such as page navigation and access to secure areas of the website. The website cannot function properly without these cookies.


Statistical cookies help us understand how visitors use the website by collecting and reporting data anonymously. These cookies therefore do not collect any personal data from visitors.

Cookies are small text files that can be used by websites to make user experiences more efficient. By law, we may store cookies on your device if they are strictly necessary for the use of the website. These are the functional cookies. We need your consent for all other types of cookies. These cookies are named as: preferences and statistics and you do not have to accept them. This website uses different types of cookies. Some cookies are placed by third party services that are displayed on our pages.

This website uses cookies to improve your experience. You can manage your options here.